nadifloxacin has been researched along with Cancer of Gastrointestinal Tract in 1 studies
nadifloxacin: (R)-isomer does not induce chromosomal aberrations, unlike (S)-isomer; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Severe exanthema (grade III/IV) develops in about 9-19 % of patients with the necessity of cetuximab dose reduction or cessation." | 1.39 | Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective. ( Berger, MR; Galle, PR; Gockel, I; Graf, C; Herzog, J; Lang, H; Möhler, M; Schimanski, CC; Theobald, M; Wehler, TC, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wehler, TC | 1 |
| Graf, C | 1 |
| Möhler, M | 1 |
| Herzog, J | 1 |
| Berger, MR | 1 |
| Gockel, I | 1 |
| Lang, H | 1 |
| Theobald, M | 1 |
| Galle, PR | 1 |
| Schimanski, CC | 1 |
1 other study available for nadifloxacin and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective.
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antibo | 2013 |